Atsena Therapeutics Completes Key Step in XLRS Gene Therapy Trial, Shows Promising Results
December 16, 2024
The therapy utilizes a novel AAV.SPR capsid, which allows for efficient spreading beyond the injection site, enhancing gene therapy's effectiveness while minimizing surgical risks.
Dr. Kenji Fujita, Atsena's Chief Medical Officer, stated that the results validate the efficacy of their novel capsid for treating inherited retinal diseases and will guide the next phase of the trial.
The company anticipates gaining valuable insights from the trial to advance ocular gene therapy approaches.
Atsena Therapeutics announced the completion of dosing in Part A of the LIGHTHOUSE study, a Phase I/II trial for the treatment of X-linked retinoschisis (XLRS) using their gene therapy product, ATSN-201.
The LIGHTHOUSE study is an open-label trial evaluating the safety and tolerability of ATSN-201 in male patients aged six and older, with enrollment currently ongoing.
The trial assesses three dose levels of ATSN-201, administered as a subretinal injection, in nine adult participants diagnosed with XLRS.
Results from Part A of the study indicated both structural and functional improvements in the treated patients, with no serious adverse events reported.
XLRS is a genetic condition affecting approximately 30,000 males in the U.S. and EU, typically diagnosed in early childhood, leading to impaired vision and eventual blindness.
ATSN-201 has received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance in treating rare conditions.
Patrick Ritschel, CEO of Atsena, expressed optimism about the study's milestone for XLRS patients, noting the absence of approved treatments and the potential benefits for other inherited retinal diseases.
Atsena Therapeutics is committed to developing innovative gene therapies for inherited retinal diseases, aiming to improve patient outcomes through advanced research.
ATSN-201 is designed to deliver therapeutic levels of gene expression in the central retina's photoreceptors, representing a promising advancement in gene therapy.
Summary based on 3 sources
Get a daily email with more Science stories
Sources

occular surgery news logo • Dec 17, 2024
Atsena completes dosing in part A of X-linked retinoschisis gene therapy trial
